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Original Article

Unexpected Abrupt Increase in Left
Ventricular Assist Device Thrombosis
Randall C. Starling, M.D., M.P.H., Nader Moazami, M.D., Scott C. Silvestry, M.D.,
Gregory Ewald, M.D., Joseph G. Rogers, M.D., Carmelo A. Milano, M.D.,
J. Eduardo Rame, M.D., Michael A. Acker, M.D., Eugene H. Blackstone, M.D.,
John Ehrlinger, Ph.D., Lucy Thuita, M.S., Maria M. Mountis, D.O.,
Edward G. Soltesz, M.D., M.P.H., Bruce W. Lytle, M.D.,
and Nicholas G. Smedira, M.D.

A BS T R AC T
BACKGROUND

We observed an apparent increase in the rate of device thrombosis among patients
who received the HeartMate II left ventricular assist device, as compared with preapproval clinical-trial results and initial experience. We investigated the occurrence of
pump thrombosis and elevated lactate dehydrogenase (LDH) levels, LDH levels presaging thrombosis (and associated hemolysis), and outcomes of different management
strategies in a multi-institutional study.
METHODS

We obtained data from 837 patients at three institutions, where 895 devices were
implanted from 2004 through mid-2013; the mean (±SD) age of the patients was 55±14
years. The primary end point was confirmed pump thrombosis. Secondary end points
were confirmed and suspected thrombosis, longitudinal LDH levels, and outcomes
after pump thrombosis.
RESULTS

A total of 72 pump thromboses were confirmed in 66 patients; an additional 36 thromboses in unique devices were suspected. Starting in approximately March 2011, the occurrence of confirmed pump thrombosis at 3 months after implantation increased from
2.2% (95% confidence interval [CI], 1.5 to 3.4) to 8.4% (95% CI, 5.0 to 13.9) by January 1, 2013. Before March 1, 2011, the median time from implantation to thrombosis was
18.6 months (95% CI, 0.5 to 52.7), and from March 2011 onward, it was 2.7 months
(95% CI, 0.0 to 18.6). The occurrence of elevated LDH levels within 3 months after implantation mirrored that of thrombosis. Thrombosis was presaged by LDH levels that
more than doubled, from 540 IU per liter to 1490 IU per liter, within the weeks before
diagnosis. Thrombosis was managed by heart transplantation in 11 patients (1 patient
died 31 days after transplantation) and by pump replacement in 21, with mortality equivalent to that among patients without thrombosis; among 40 thromboses in 40 patients
who did not undergo transplantation or pump replacement, actuarial mortality was
48.2% (95% CI, 31.6 to 65.2) in the ensuing 6 months after pump thrombosis.
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CONCLUSIONS

The rate of pump thrombosis related to the use of the HeartMate II has been increasing at our centers and is associated with substantial morbidity and mortality.
n engl j med 370;1
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he HeartMate II (Thoratec), a
small, axial-flow left ventricular assist
device (LVAD), rapidly became integral to
the treatment of patients with advanced heart
failure.1 Pivotal trials and postmarketing approval
studies of the HeartMate II provide a reference
occurrence of thrombosis of 2 to 4%2-4; however,
an unexpected abrupt increase in the incidence
of pump thrombosis was observed in a singlecenter quality review. To confirm that this finding was not an isolated phenomenon, two additional experienced centers pooled data to investigate
the incidence of pump thrombosis and of elevated lactate dehydrogenase (LDH) levels as its clinical biomarker (indicating hemolysis), LDH levels
that may presage thrombosis, and outcomes of
thrombosis-management strategies.

Me thods
Patients

A total of 895 HeartMate II LVADs were implanted in 837 patients at three institutions: Cleveland
Clinic from October 2004 through February 2013
(296 devices in 280 patients), Washington University Barnes–Jewish Hospital from January 2004
through April 2013 (307 devices in 287 patients),
and Duke University Medical Center from May
2005 through May 2013 (292 devices in 270 patients). At the three respective institutions, the mean
(±SD) ages of the patients were 54±14, 54±13, and
58±14 years, with an overall average of 55±14 years;
19.3%, 16.4%, and 27.8% of the patients were
women, with an overall average of 21.0%.
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The electronic medical-records systems at the
hospitals were queried to extract serial values of
LDH during HeartMate II support. We obtained
12,379 LDH measurements for 568 devices (275
devices at Cleveland Clinic, 24 at Barnes–Jewish
Hospital [only for some cases of confirmed thrombosis], and 269 at Duke University Medical Center).
There were typically 12 to 24 LDH measurements
per device (see Fig. S1 in the Supplementary Appendix, available with the full text of this article at
NEJM.org).
End Points

The primary end point was confirmed pump
thrombosis. Secondary end points were confirmed
plus clinically suspected pump thrombosis, elevated LDH levels, the pattern of LDH levels leading up to pump thrombosis, and outcomes after
the management of pump thrombosis (pump replacement or explantation, urgent heart transplantation, medical treatment, or death).
Confirmed pump thrombosis was defined as a
thrombus found on the blood-contacting surfaces
of the HeartMate II, its inflow cannula, or its outflow conduit at pump replacement, urgent transplantation, or autopsy (Appendix S1 and Fig. S2
in the Supplementary Appendix). Suspected pump
thrombosis was defined as a clinical diagnosis
of pump-related malfunction in which the clinical or device variables suggested a thrombus on
the blood-contacting surfaces of the pump, cannulae, or grafts (Appendix S1 in the Supplementary Appendix).
Management of Pump Thrombosis

Study Data

Limited, partially deidentified data were provided
for analysis under data-use agreements and with
approval from the institutional review board at
each institution to use these data in research; the
requirement to obtain informed consent from the
patients was waived. Variables in common across
the three institutions included the date of HeartMate II implantation, the number of HeartMate II
devices each patient had previously received, age
at each HeartMate II implantation, sex, bridge-totransplantation versus destination therapy as the
indication for mechanical circulatory support, and
surgeon. The medical records of patients with
confirmed or suspected pump thrombosis were
scrutinized by investigators at each site to verify
diagnostic evidence.
34
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Clinically suspected pump thrombosis was managed by means of intravenous anticoagulation
therapy, thrombolytic agents, and antiplatelet therapy; pump replacement or explantation; or urgent
heart transplantation. In general, centers followed
the guidelines developed by a committee of clinical experts,5 although the details of the approach
and management strategies were specific to each
institution and varied over time (Appendix S2 in
the Supplementary Appendix).
Follow-up

Follow-up assessment of clinical outcomes and
laboratory measurements occurred at intervals
of 3 months or less after the device implantation.
The common closing date for patients at the Cleveland Clinic was March 5, 2013; for those at
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Barnes–Jewish Hospital, September 10, 2013; and
for those at the Duke University Medical Center,
May 16, 2013. The median follow-up at the three
institutions was 7.8 months, 10.7 months, and
10.4 months, respectively; the three institutions
had 278 patient-years, 376 patient-years, and 393
patient-years of follow-up data available for analysis, respectively.
Statistical Analysis

The risk of pump thrombosis was estimated from
the pooled multicenter data and was also estimated separately for each institution. Kaplan–Meier,6
parametric hazard,7 and nonparametric random
survival forest8-10 analyses (Appendix S1 in the
Supplementary Appendix) were based on data for
unique devices rather than data for unique patients, with time zero defined as the date of implantation of each HeartMate II. Data were censored at transplantation, death, pump replacement,
pump removal without replacement (allowed
because of left ventricular recovery), and end of
follow-up.
The date of implantation was incorporated into
a parametric hazard model to identify a changing
incidence of pump thrombosis across time. To
corroborate parametric findings without making
model assumptions, the data were also analyzed
with the use of the random survival forest method
(Appendix S1 in the Supplementary Appendix).
We hypothesized that the LDH level, which is
indicative of hemolysis caused by thrombus formation in the pump, may independently corroborate an increasing incidence of pump thrombosis.
Therefore, each patient’s sequence of LDH measurements was scanned algorithmically for LDH
levels of more than 1000 IU per liter. Single-sample
spikes were ignored as probable sample hemolysis,
although the algorithm included samples immediately proximate to death, urgent transplantation,
device replacement, or explantation. These data
were analyzed as time-related events, exactly as
for pump thrombosis.
For confirmed thrombosis, a landmark analysis of LDH measurements was performed with
the date of pump thrombosis set as time zero.
The preceding 3-month longitudinal sequence of
measurements for each device was connected by
straight lines. A locally estimated scatterplot
smoother (loess)11 was then fitted to the ensemble of line segments.
Time zero for death after confirmed pump
n engl j med 370;1

thrombosis was the date of suspected pump
thrombosis, even if confirmation subsequently
occurred at the time of pump replacement, urgent transplantation, or autopsy. Data were censored 30 days after transplantation or pump replacement to capture the risks of these procedures.
The Kaplan–Meier method was used to estimate
time-related mortality. For reference, the competing risk of death during HeartMate II support
without pump thrombosis was generated.12
Data were analyzed with the use of SAS software, version 9.2 (SAS Institute), and R software,
version 3.0.2.13 For internal consistency, uncertainty of estimates is expressed uniformly by
means of 95% confidence intervals or bands similar to ±2 SE.

R e sult s
Overall Incidence of Pump Thrombosis

A total of 72 confirmed pump thromboses were
observed in 66 patients, and an additional 36
thromboses in unique devices were suspected.
The risk of confirmed pump thrombosis peaked
at 1.4% per month within 1 month after implantation before decreasing to a constant risk of
0.4% per month (Fig. S3A in the Supplementary
Appendix), with estimated occurrences of pump
thrombosis of 4.7% during HeartMate II support
for 6 months, 7.5% during 12 months of support, and 12.3% during 24 months of support
(Fig. S3B in the Supplementary Appendix). This
pattern of risk was consistent among the three
institutions (Fig. S4 in the Supplementary Appendix). It also characterized the combined risk
of confirmed plus suspected pump thrombosis,
which rose to 2.0% per month within 1 month
after implantation, then fell to 0.7% per month
after 6 to 8 months, with estimated occurrences
of 7.1% during HeartMate II support for 6 months,
11.3% during 12 months of support, and 18.3%
during 24 months of support (Fig. S5 in the Supplementary Appendix).
Changing Incidence of Pump Thrombosis

The occurrence of confirmed pump thrombosis
increased steeply after approximately March 2011,
from 2.2% (95% confidence interval [CI], 1.5 to
3.4) at 3 months after implantation to 8.4%
(95% CI, 5.0 to 13.9) by January 2013 (Fig. 1, and
Table S1 and Fig. S6 and S7 in the Supplementary Appendix). A similar pattern was observed
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Devices with Confirmed Pump Thrombosis (%)

LDH Level Presaging Pump Thrombosis
30

On average, the LDH level increased from 540 IU
per liter (95% CI, 388 to 695) to 1490 IU per liter
(95% CI, 1350 to 1600) in the 6 weeks leading
up to confirmed pump thrombosis. This finding
was consistent across institutions (Fig. 4, and
Fig. S14 in the Supplementary Appendix).
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Figure 1. Overall Occurrence of Confirmed Pump Thrombosis at 3 Months
after HeartMate II Implantation.
Dashed lines represent the 95% confidence interval. There was a steep increase in the occurrence of thrombosis starting in early 2011. The inset
shows the changing occurrence of confirmed pump thrombosis according
to study site (Cleveland Clinic [CC], Barnes–Jewish Hospital [BJH], and
Duke University Medical Center [Duke]).

at all three institutions (Fig. 1) and for multiple
surgeons (Fig. S8 in the Supplementary Appendix).
The median time from implantation to confirmed pump thrombosis decreased from 18.6
months (95% CI, 0.5 to 52.7) before March 2011
to 2.7 months (95% CI, 0.0 to 18.6) during and
after March 2011. What had been a constant risk
of confirmed pump thrombosis of 0.4% per month
(95% CI, 0.3 to 0.5) after implantation developed
into an early hazard that peaked at 2 months
and then fell to a sustained 0.6% per month
(95% CI, 0.3 to 1.2) (Fig. 2); this risk was consistent across institutions (Fig. S9 in the Supplementary Appendix). This pattern of change in
the incidence of confirmed pump thrombosis
also characterized the rate of confirmed plus
suspected events (Table S2 and Fig. S10, S11, and
S12 in the Supplementary Appendix).
Changing Occurrence of Elevated LDH Levels

The graph of the occurrence of LDH levels above
1000 IU per liter within 3 months after implantation was nearly superimposable on the graph
of the occurrence of confirmed pump thrombosis. The LDH data showed a parallel tendency for
elevations to occur early after implantation beginning in approximately March 2011 (Fig. 3,
and Fig. S13 in the Supplementary Appendix).
36
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There were 72 pump thromboses in 66 patients.
A total of 11 pump thromboses were managed
by heart transplantation in 11 patients (1 patient
died 31 days after transplantation). A total of 21
pump thromboses were managed by pump replacement in 19 patients (1 patient died >30 days
after the pump replacement, and 1 underwent
3 replacements). Of 40 thromboses not managed by heart transplantation or pump replacement, 2 thromboses in 2 patients were managed
with pump removal, because left ventricular function had improved; 38 pump thromboses were
managed medically in 38 patients (4 of whom
had undergone prior device replacement), of whom
19 died. Medical management included the augmentation of anticoagulation therapy and thrombolytic agents, which in some cases was effective
and stabilized the patient’s clinical course; however, some patients elected withdrawal of care
on the basis of futility.
As compared with mortality during HeartMate
II support among patients without confirmed
pump thrombosis, the actuarial mortality after
confirmed pump thrombosis at various time
points was higher: 6.9% (95% CI, 5.4 to 8.8)
versus 17.7% (95% CI, 9.7 to 30.1) at 30 days,
9.7% (95% CI, 7.9 to 11.9) versus 22.4% (95% CI,
13.0 to 35.8) at 60 days, 12.2% (95% CI, 10.1 to
14.6) versus 27.4% (95% CI, 16.6 to 41.5) at 90
days, and 16.8% (95% CI, 14.3 to 19.6) versus
35.6% (95% CI, 22.9 to 50.7) at 180 days (Fig. S15A
in the Supplementary Appendix). There was considerable variation in outcomes (Fig. S15B in the
Supplementary Appendix), depending on candidacy for urgent transplantation or pump replacement. Mortality at 6 months among patients
treated with device replacement or transplantation was similar to that among patients who did
not have device thrombosis (Fig. 5), but mortality
was 48.2% (95% CI, 31.6 to 65.2) among patients
with device thrombosis who were not treated with
these methods, and this elevated mortality was
consistent across institutions (Fig. S15C in the
Supplementary Appendix).
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Figure 2. Occurrence and Incidence of Confirmed Pump Thrombosis Stratified According to Implantation Date.
The occurrence of confirmed pump thrombosis was stratified according to whether the date of implantation was before March 1, 2011 (gray line), or on or after that date (black line). Each symbol represents an event, and I bars indicate 95% confidence intervals. The parametric estimates (solid lines) are shown with the 95% confidence intervals
(dashed lines). The inset shows the instantaneous risk of pump thrombosis before March 1, 2011, which was constant at 0.4% per month, and the risk during or after March 2011, which peaks early after implantation before falling
to a sustained rate of 0.6% per month.

Discussion
Approval of the HeartMate II by the Food and
Drug Administration (FDA) has had a substantial
impact on the care of patients with advanced
heart failure. LVAD therapy is an important advance that is used to prolong survival and improve quality of life. Refinement of all therapeutic
innovations evolves as clinicians gain experience
with and an understanding of device-associated
complications and their management.
The rate of pump thrombosis with the HeartMate II began increasing in March 2011 and had
not plateaued as of mid-2013. Confirmed pump
thrombosis occurs early and peaks 1 month after
implantation, with a reduction in risk by 6 months.
This rate exceeds the rates previously observed at
our centers and reported in clinical trials.14 The
n engl j med 370;1

incidence of elevated LDH levels mirrors this increased rate, making it a useful clinical biomarker
of hemolysis associated with pump thrombosis.
Patients with pump thrombosis have increased
morbidity and substantially increased mortality
unless the pump is replaced or cardiac transplantation is performed.
The initial analysis that revealed this sudden
increase in the incidence of pump thrombosis
was a clinical quality review at a single center
(Cleveland Clinic). To confirm and strengthen
those findings, we pooled data from two additional experienced LVAD centers and found similar results. The initial findings at the Cleveland
Clinic were immediately sent to Thoratec and to
the FDA. Statisticians at the Interagency Registry
for Mechanically Assisted Circulatory Support
(INTERMACS) conducted an analysis of 6251
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Figure 3. Elevated Lactate Dehydrogenase (LDH) Levels within 3 Months
after HeartMate II Implantation.
The overall estimate of the percentage of patients with LDH levels of more
than 1000 IU per liter within 3 months after the implantation of a HeartMate II is shown, without regard to diagnosis of confirmed or suspected
pump thrombosis. The parametric estimate is shown (solid line) with the
95% confidence interval (dashed lines). The occurrence of elevated LDH
levels increased steadily starting in 2011, which was similar to the pattern
observed for pump thrombosis. The inset shows changes in occurrence according to study site.
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Figure 4. LDH Values before Confirmed Pump Thrombosis.
The time of pump thrombosis (time zero) is shown at the right side of the
graph, and LDH values up to 3 months before confirmed thrombosis are
shown. The solid line represents the estimate of the LDH level, as generated by the locally estimated scatterplot smoother (loess), and the gray band
represents the bootstrapped 95% confidence interval.
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implantations performed from April 1, 2008, to
September 1, 2012, and found that the occurrence of pump thrombosis increased from 2%
before May 2011, to 5% from May onward.15
This observation is reported on the INTERMACS
website.15
The INTERMACS captures data on the occurrence of suspected pump thrombosis on the
basis of device replacement or death attributable
to thrombus. Our study also included 11 of 66
patients with device thrombosis (16.7%) who
were rescued with urgent heart transplantation.
Examination of the incidence of device thrombosis with the use of the implantation date as a
continuous variable and with a description of
outcomes after therapeutic intervention provides a more complete picture of the scope and
risks of device thrombosis. Thus, we believe the
INTERMACS data may not accurately reflect the
actual occurrence of pump thrombosis and its
risks. Although the INTERMACS is a valuable
resource, event reporting is voluntary, and definitions of adverse events are evolving. By combining data from three high-volume institutions,
we reduced the likelihood that our observations
are an isolated single-center effect related solely
to the management approach.
We found that a sharp rise in LDH levels occurring within the first weeks after implantation
often preceded and heralded confirmed pump
thrombosis. Our findings are consistent with
those of the University of Michigan.16
Pump function and reliability are related to
the complex interaction between implantation
techniques17 and anatomical constraints; patientlevel factors such as infection, bleeding, and
adequacy of anticoagulation; pump settings; and
device design and manufacturing.18 During the
course of the study, implantation techniques did
not change, and we could find no association
between pump thrombosis and the surgeon performing the implantation (Fig. S8 in the Supplementary Appendix). Design changes, including
modification of the outflow graft and bend relief, inflow conduit, and software, were introduced during the study period but, to our knowledge, have not been directly linked to pump
thrombosis.
We have collectively observed, most commonly at explantation, that there is a deposition
of material (fibrin and denatured protein) in
proximity to the inflow bearing (Fig. S2 in the
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70
Neither transplantation
nor replacement

60

Patients Who Died (%)

Supplementary Appendix), which depends on
fluid for lubrication and flow to dissipate heat.
Heat generation and the subsequent deposition
of fibrin around the bearing narrows the inflow
pathway, increasing shear stress on the red cells
and, if the deposition is large enough, decreasing the ability of the pump to unload the left
ventricle. The bearing–fibrin deposition theory
could explain the hemolysis that develops as
thrombus deposition begins, escalates into
frank pump thrombosis, and culminates in hemodynamic compromise. We theorize that the
changes occur in three stages: the initial stage
is hemolysis with thrombus deposition but no
hemodynamic compromise (thrombus formation); this may progress to hemolysis and abnormal pump function (incomplete thrombosis);
and ultimately, complete thrombosis and pump
stoppage may occur.
Any perturbation that might reduce flow and
heat dissipation from the bearing, or inadequate
anticoagulation, might represent precipitating
conditions. Known clinical factors that might
transiently impair flow include the development
of aortic regurgitation, arrhythmias, kinking of
the inflow graft because of bending, and hypovolemia. As of this writing, the exact cause of
the increased rate of pump thrombosis remained
unknown.
This is a three-institution retrospective study
with known inherent limitations. However, unlike INTERMACS, we have extensive data on LDH
levels and can carefully scrutinize patient records.
The definitions of confirmed and suspected
pump thrombosis have been revised recently by
the INTERMACS steering committee to reflect
elevated LDH levels as a marker of hemolysis.16
These definitions were not available prospectively for this study but were used in the individual review of potential cases of pump thrombosis. This may explain differences between our
data and INTERMACS reported events. However,
it is possible that we underdiagnosed pump
thrombosis before 2011, and clinically evident
pump thrombosis does not develop in all patients with increased LDH levels. In addition, in
the case of patients who died with the LVAD in
situ, if an autopsy was not performed, visual
confirmation could not take place.
Anticoagulation protocols changed during
the course of this analysis, with some variation
among institutions (Table S4 in the Supplemen-
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Figure 5. Mortality According to Management Strategy after Confirmed
Pump Thrombosis.
Squares indicate deaths after heart transplantation or pump replacement,
and diamonds indicate deaths of patients who did not undergo heart
transplantation or pump replacement, with the horizontal axis truncated
at 6 months. For reference, triangles indicate deaths without confirmed
pump thrombosis during HeartMate II support from the time of implantation (gray). Symbols represent nonparametric estimates, and I bars 95%
confidence intervals. The dashed line represents patients for whom followup data were available and who remained alive.

tary Appendix). Nonetheless, our data suggest that
the HeartMate II may have a more narrow tolerance with respect to thrombus formation than
originally understood and may be vulnerable to
the timing and intensity of anticoagulation.
In conclusion, we observed an increasing incidence of early thrombosis with the HeartMate
II that is associated with substantial morbidity
and mortality. Costly device replacement or urgent transplantation can be lifesaving, although
with morbidity. Further investigation of predisposing patient and device factors and preventive
and therapeutic strategies are urgently needed to
resolve this important safety issue. We recognize
that LVADs provide life-sustaining treatment for
many patients with advanced heart failure. However, recommendations for LVAD therapy should
account for this updated risk–benefit profile.
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Note added in proof: Pursuant to a data-sharing
agreement with the University of Pennsylvania,
we have completed a preliminary analysis of 150
unique devices (placed between November 1,
2005, and September 3, 2013) in 148 patients
who had 15 thrombotic events (closing date,
October 28, 2013). Similar to the findings in our
study, the event rate has increased abruptly and
unexpectedly, with a rate of confirmed thrombosis that continues to rise.
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